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Summary
Background:  Acinetobacter  baumannii  has  successfully  become  a  signiﬁcant  noso-
comial  pathogen  because  of  its  remarkable  ability  to  acquire  antibiotic  resistance
and  to  survive  in  nosocomial  environments.  This  study  aimed  to  determine  the
drug  susceptibility  patterns  and  the  distribution  of  four  subgroups  of  carbapenem-PCR
hydrolyzing  class  D  -lactamases  (OXA-carbapenemases),  as  well  as  their  insertion
sequences  (ISAba1),  among  A.  baumannii  nosocomial  isolates  from  a  Saudi  tertiary
care  hospital.
Methods:  A  total  of  108  non-duplicate  A.  baumannii  isolates  were  identiﬁed,  and
their  susceptibilities  to  different  antibiotics  were  determined  using  the  breakpoint
method.  Isolates  were  then  subjected  to  multiplex-PCR  targeting  blaOXA genes.
Abbreviations: OXA-carbapenemases, carbapenem hydrolyzing class D -lactamases; ISAba1, insertion sequence.
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cinetobacter  baumannii  is  an  important  oppor-
unistic  pathogen  and  is  often  involved  in  various
osocomial infections,  such  as  bacteremia,  urinary
ract infection,  secondary  meningitis,  surgical
ite infection,  and  nosocomial  and  ventilator-
ssociated pneumonia,  especially  in  patients
dmitted to  intensive  care  and  burn  units  [1].
. baumannii  is notorious  for  its  remarkable
nnate and  acquired  resistance  to  multiple  antimi-
robial  classes,  including  extended-spectrum
ephalosporins  and  carbapenems.  Resistance
o carbapenems  is  the  most  concerning,  as
arbapenems have  a  potent  activity  against
cinetobacter  spp  and  are  often  used  as  a  last
esort for  the  treatment  of  infections  due  to
ulti-resistant A.  baumannii  isolates.  The  emer-
ence  of  carbapenem-resistant  A.  baumannii
as been  described  as  the  sentinel  event  of  antimi-
robial resistance  [2,3]. Reports  from  different
egions in  Saudi  Arabia  have  shown  imipenem  (IMP)
esistance  rates  of  2.6—13.1%  [4,5].
Carbapenem  resistance  in  A.  baumannii  can
e mediated  by  various  mechanisms,  including
mpermeability  due  to  the  loss  of  one  of  its  major
orins and,  possibly,  efﬂux,  as  shown  recently
or meropenem  [1,6]. Most  frequently,  though,  it
s mediated  through  the  enzymatic  hydrolysis  of
he drug,  particularly  by  carbapenem-hydrolyzing pannii  243
he  isolates  showed  resistance  to  different  antibiotics.
o  colistin,  meropenem,  imipenem  and  trimethoprim—
 50,  48.1  and  34.3%,  respectively.  All  isolates  possessed
 carbapenem-resistant  isolates,  48  isolates  (85.7%)  car-
(5.4%)  carried  blaOXA-40-like and  two  isolates  (3.6%)  had
a1  element  was  found  upstream  of  the  blaOXA-23 and
nd  3  (5.4%)  isolates,  respectively,  while  it  was  detected
one  (1.8%)  isolate.
her  illustrate  the  challenge  of  increasing  carbapenem-
isolates  in  Saudi  Arabia.  The  high  distribution  of  class
genes,  mainly  ISAba1/OXA-23  and  ISAba1/OXA-24  car-
and  presents  an  emerging  threat  in  our  hospital.  Local
ential  to  help  control  carbapenem-resistant  A.  bauman-
d  to  prevent  DNA  exchange  among  endemic  nosocomial
ziz  University  for  Health  Sciences.  Published  by  Elsevier
lass  D  -lactamases  (oxacillinases).  Oxacillinases
an be  grouped  into  six  subclasses:  chromosomal
XA-51-like,  acquired  OXA-23-like  (OXA-23,  OXA-
7 and  OXA-49),  OXA-24/40-like  (OXA-24,  OXA-25,
XA-26,  OXA-40  and  OXA-72),  OXA-58-like,  OXA-
43-like,  and  OXA-235-like  (OXA-235,  OXA-236
nd OXA-237)  -lactamases  [7,8]. Although  they
re weak  carbapenem  hydrolysers,  they  confer
esistance when  over-expressed  as  a result  of  their
ssociation  with  mobile  elements,  such  as  ISAba1,
hich carries  a strong  promoter  [9].
Carbapenem  resistance  due  to  OXA-
arbapenemases  has  been  reported  in  diverse
eographical regions  [1,10—12]. There  is  little
nformation on  the  prevalence  and  distribution  of
-lactamases  in  A.  baumannii  from  Saudi  Arabia,
lthough  resistance  is  frequent.  However,  few
tudies  have  reported  the  frequent  isolation  of
XA-23-producing  A.  baumannii  in  Saudi  Arabia,
uggesting  that  blaOXA-23-carrying  A.  baumannii
trains have  become  endemic  [13—15].  Con-
ersely, reports  concerning  the  blaOXA-24-like and
laOXA-58-like genes  are  limited  to  the  description
f sporadic  isolates  [13—15].
The present  study  aimed  to  determine  the
rug susceptibility  patterns  and  the  distribution
f four  subgroups  of  OXA-carbapenemases  and  the
nsertion sequence,  ISAba1,  among  A.  baumannii
osocomial isolates  from  a  Saudi  tertiary  care  hos-
ital over  a 6-month  period.
F.M.  Elabd  et  al.
Table  1  Sequences  of  primers  used  in  this  study  for
multiplex  PCR  for  detection  of  genes  encoding  oxacil-
linases  in  A.  baumannii  isolates  [9,19].
Primer  Nucleotide  sequence  (5′—3′)
OXA51-F  TAA  TGC  TTT  GAT  CGG  CCT  TG
OXA51-R  TGG  ATT  GCA  CTT  CAT  CTT  GG
OXA23-F  GAT  CGG  ATT  GGA  GAA  CCA  GA
OXA23-R  ATT  TCT  GAC  CGC  ATT  TCC  AT
OXA24-F  GGT  TAG  TTG  GCC  CCC  TTA  AA
OXA24-R  AGT  TGA  GCG  AAA  AGG  GGA  TT
OXA58-F  AAG  TAT  TGG  GGC  TTG  TGC  TG
OXA58-R  CCC  CTC  TGC  GCT  CTA  CAT  AC
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Materials and methods
This  study  was  conducted  at  Aseer  Central  Hos-
pital (Abha,  Saudi  Arabia),  which  is  a  500-bed
tertiary care  hospital  located  in  Abha  City,  over
a 6-month  period  from  October  2013  to  March
2014. Non-duplicate  A.  baumannii  strains  were
isolated  from  blood,  urine,  respiratory  secretions
(sputum and  tracheal  aspirate),  stool,  pus,  throat
swabs,  ascetic  ﬂuid  and  the  tips  of  central  venous
catheters.  The  study  included  different  patients
who were  hospitalized  for  ≥48  h and  classiﬁed
according to  the  Centers  for  Disease  Control  and
Prevention/National  Healthcare  Safety  Network
(CDC/NHSN) criteria  [16]. The  strains  were  iden-
tiﬁed  using  conventional  biochemical  tests  [17],
the API  20NE  (Biomerieux)  and  MicroScan  Walkaway
automated  systems  (Dade  Behring,  CA),  according
to the  manufacturers’  instructions.
Antimicrobial susceptibility testing
Antimicrobial  susceptibility  testing  was  per-
formed with  the  breakpoint  method,  using  the
MicroScan Walkaway  automated  systems,  and
the E-test  minimum  inhibitory  concentration
method,  using  E-test  strips  (AB  Biodisk,  Slona,
Sweden) on  Mueller—Hinton  agar  plates  per  the
guidelines  of  the  Clinical  and  Laboratory  Standards
Institute [18]. The  antibiotics  tested  included
amikacin, ceftazidime,  cefotaxime,  cefepime,
gentamicin, tobramycin,  imipenem,  meropenem
(MEM), piperacillin,  ciproﬂoxacin,  levoﬂoxacin,
trimethoprim—sulfamethoxazole  and  colistin.
All isolates  (one  isolate/patient)  were  sent  to  the
microbiology  department  of  the  Najran  University
College of  Medicine  for  molecular  analysis.
Identiﬁcation of the oxacillinases genes
All  isolates  were  subjected  to  multiplex  PCR  to
detect blaOXA-51-like,  blaOXA-23-like,  blaOXA-40-like and
blaOXA-58-like genes,  as  previously  reported  [19]. All
primers used  in  this  study  are  listed  in  Table  1.
PCR was  carried  out  in  a  thermocycler  (Cyclogene,
Techne, UK).  A  single  reaction  mixture  contained:
30 ng  of  genomic  DNA,  20  pM  of  each  primer,  10  l  of
reaction  buffer,  3  l  of  25  mM  MgCl2, 1  l  of  dNTPs
and 0.25  l  of  go  Taq  Polymerase  (Promega,  USA),
with a  ﬁnal  volume  of  50  l.  Initial  denaturation
(94 ◦C  for  3  min)  was  followed  by  30  cycles  of  ampli-
ﬁcation. Each  cycle  consisted  of  94 ◦C  for  25  s,  52 ◦C
for 40  s,  and  72 ◦C  for  50  s.  A  ﬁnal  extension  step
(72 ◦C  for  5  min)  completed  the  ampliﬁcation.
r
s
(
a
lISAb1-F  CAC  GAA  TGC  AGA  AGT  TG
ISAb1-R  CGA  CGA  ATA  CTA  TGA  CAC
creening for the presence of ISAba1
.  baumannii  strains  were  assayed  for  the  ISAba1
equence  by  PCR  with  primers  ISAba1-F  and  ISAba1-
 (Table  1) giving  rise  to  a  549-bp  fragment.  A  single
eaction  mixture  contained:  30  ng  of  genomic  DNA,
0 pM  of  each  primer,  5  l  of  reaction  buffer,  1.5  l
f 25  mM  MgCl2, 0.5  l  of  dNTPs  and  0.125  l  of  go
aq Polymerase  (Promega),  with  a ﬁnal  volume  of
5 l.  The  ampliﬁcation  conditions  were  as  follows:
nitial  denaturation  (95 ◦C  for  5  min)  was  followed
y 35  cycles  of  ampliﬁcation.  Each  cycle  consisted
f 95 ◦C  for  45  s,  56 ◦C  for  45  s,  72 ◦C  for  3  min  and  a
nal extension  step  at  72 ◦C  for  5  min  [27]. Whether
SAba1 preceded  the  OXA  carbapenemase  genes
as determined  using  PCR  experiments  by  combina-
ions of  the  ISAba1-F  and  reverse  primers  designed
or the  blaOXA-23-like,  blaOXA-24-like,  blaOXA-51-
ike and  blaOXA-58-like  genes  [9].
esults
 total  of  108  non-duplicate  A.  baumannii  iso-
ates were  collected  during  the  study  period,
ainly recovered  from  respiratory  (52.8%),  wound
29.6%)  and  urinary  tract  (11.1%)  infections.  The
rimary clinical  specimens  included  tracheal  aspi-
ate (31.5%),  sputum  (29.6%),  wound  swab  (22.2%)
nd urine  (11.1%).  The  clinical  characteristics  of
. baumannii-infected  hospitalized  patients  were
nalyzed.  The  age  of  the  patients  ranged  from  4  to
5 years  (median,  45  years);  and  72  (66.7%)  were
ales.  The  majority  (66;  61.1%)  of  isolates  were
ecovered  from  patients  in  the  ICU,  followed  by
urgical  (19;  17.6%)  and  medical  (13;  12%)  wards
Table  2).
The antimicrobials  tested  and  the  percent-
ges of  isolates  determined  to  be  resistant  are
isted  in  Table  3. Overall,  greater  than  75%  of
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Table  2  Demographic  and  clinical  characteristics  of
study  patients.
Characteristic  No.  (%)
Median  age  in  years  (Range)  45  (4—85)
Male  gender  (%)  72  (66.7)
Type  of  infectiona
RTI  57  (52.8)
SSI  32  (29.6)
UTI  12  (11.1)
Primary  bacteraemia 7  (6.5)
Type  of  specimen
Tracheal  aspirate  34  (31.5)
Sputum  26  (24.1)
Wound  swab  24  (22.2)
Blood  6  (5.6)
Urine  12  (11.1)
Othersb 6  (5.6)
Ward  admission
Medical  13  (12)
Surgical  19  (17.6)
Pediatrics  10  (9.3)
ICU  66  (61.1)
Prior  antibiotic  therapy  52  (48.1)
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Table  4  Distribution  of  OXA-type  -lactamase  genes
in  56  carbapenem-resistant  A.  baumannii  nosocomial
isolates.
blaoxa allele  No.  (%)
blaoxa-51 only  2  (3.6%)
ISAba1-blaoxa-51 1  (1.8%)
blaoxa-51/blaoxa-23 8  (14.3%)
blaoxa-51/ISAba1-blaoxa-23 40  (71.4%)
blaoxa-51/ISAba1-blaoxa-24 3  (5.4%)
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tRTI, respiratory tract infection; SSI, skin and soft tissue
infection; UTI, urinary tract infection.
b Others; 3 ascitic ﬂuid, 2 stool and one CSF samples
ll  isolates  was  resistant  to  extended-spectrum
ephalosporins,  aminoglycosides  and  ﬂuoro-
uinolones. The  rates  of  susceptibility  to  colistin,
EP, IMP  and  trimethoprim—sulfamethoxazole
ere 95.6,  50,  48.1  and  34.3%,  respectively.
The  A.  baumannii  isolates  were  investigatedor the  presence  of  OXA-type  carbapenemases
Table  4).  All  isolates  harbored  the  naturally  occur-
ing blaOXA-51-like gene.  Of  56  carbapenem-resistant
solates, 48  isolates  (85.7%)  carried  blaOXA-23-like,
Table  3  Number  and  percentages  of  A.  baumannii
isolates  resistant  to  selected  antimicrobial  agents.
Antimicrobial  agent A.  baumannii
isolates  (n  =  108)
No.  (%)
Ceftazidime  92  (85.2)
Cefotaxime  103  (95.4)
Cefepime  97  (89.8)
Piperacillin  88  (81.5)
Imipenem  56  (51.9)
Meropenem  54  (50)
Ciproﬂoxacin  89  (82.4)
Levoﬂoxacin  93  (86.1)
Amikacine  81  (75)
Tobramycin  86  (79.6)
Gentamycin  88  (81.5)
Trimethoprim—sulfamethoxazole  71  (65.7)
Colistin  5  (4.6)
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 isolates  (5.4%)  carried  blaOXA-40-like and  two  iso-
ates (3.6%)  carried  blaOXA-58-like genes.  The  ISAba1
lement was  consistently  found  upstream  of  the
laOXA-23 and  blaOXA-24 genes  in  40  (71.4%)  and  3
5.4%) isolates,  respectively,  while  it  was  detected
pstream  of  blaOXA-51 in  only  one  (1.8%)  isolate.
iscussion
.  baumannii  has  successfully  become  a  signiﬁcant
osocomial  pathogen  because  of  its  remarkable
bility to  acquire  antibiotic  resistance  and  to  sur-
ive in  nosocomial  environments.  In  this  study,  half
f the  isolates  were  of  respiratory  origin.  The  other
solates  were  obtained  from  other  sources,  includ-
ng wounds,  urine  and  blood.  This  can  be  partly
xplained by  the  fact  that  A.  baumannii  is  the
econd most  frequent  pathogen  causing  respira-
ory tract  infections,  such  as  pneumonia,  and  was
hus more  frequently  detected  in  respiratory  sam-
les [20].  The  ﬁndings  of  this  study  showed  that
60% of  A.  baumannii  isolates  were  obtained  from
ospitalized  patients  in  ICU  wards.  This  ﬁnding  is
n line  with  previous  reports  about  the  role  of
. baumannii  in  nosocomial  infections  among  high-
isk ICU  patients  [1,21].
Overall, the  resistance  rates  of  A.  baumannii
o cephalosporins,  aminoglycosides  and  ﬂuoro-
uinolones obtained  in  this  study  were  higher  than
hose reported  in  previous  studies  in  Saudi  Ara-
ia [4,5]. Carpabenem  resistance  in  this  study  is  of
onsiderable  concern  because  this  class  of  antimi-
robial  agents  was,  until  recently,  considered  to
e among  the  most  potent  against  many  microor-
anisms, including  A.  baumannii.  In  2  recent  Saudi
tudies,  the  resistance  rates  of  A.  baumannii  to  IMP
nd MEM  were  62%  and  67%,  respectively  [13,14].
n a  4-year  Chinese  study,  carbapenem  resistance
ncreased from  15%  for  IMP  and  23%  for  MEM  in
008 to  90%  and  92%  in  2011,  respectively  [22].
n Taiwan,  the  prevalence  of  IMP-resistance  in  9
ears increased  from  3%  in  2002  to  59%  in  2010  [23].
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According  to  the  SENTRY  program,  the  resistance  to
IMP ranged  from  32.8%  in  North  America  to  51.7%
in Latin  America  [2].  Polymyxins  have  emerged  as
alternatives  against  A.  baumannii. In  this  study,
colistin  resistance  had  a  prevalence  of  4.6%.  The
SENTRY  study  reported  that  the  resistance  rate  to
polymyxin  B  ranged  from  2%  in  North  America  to
0.9% in  Europe  [2].
In this  study,  all  108  A.  baumannii  isolates
carried the  chromosomally  encoded  blaOXA-51-like
gene.  These  ﬁndings  support  those  of  other  stud-
ies demonstrating  that  the  detection  of  the
blaOXA-51-like gene  can  be  used  as  a  supplementary
tool to  identify  the  organism  at  the  species  level,
conﬁrmed  by  additional  methods  [24,25].
The most  frequent  enzymatic  mechanism  of
carbapenem resistance  in  A.  baumannii  is  the
production  of  oxacillinases,  and  several  stud-
ies have  identiﬁed  a  variety  of  oxacillinases  in
carbapenem-resistant  A.  baumannii  isolates.  The
blaOXA-23 carbapenemase-producing  A.  bauman-
nii are  becoming  widespread  globally  in  Europe,
South America,  and  Asia  [10,21,26—29]. In  this
study,  blaOXA-23 carbapenemase  was  detected  in  48
(85.7%)  of  the  56  carbapenem-resistant  isolates  and
the ISAba1  element  was  located  upstream  of  40
(71.4%)  blaOXA-23-producing  strains.  It  is  well  estab-
lished that  the  promoting  sequence  ISAba1  has  to
be present  to  increase  oxacillinase  expression  and,
consequently,  to  lead  to  the  development  of  resis-
tance to  many  antimicrobials,  creating  a serious
problem  for  the  selection  of  therapy  [1,24]. Our
data are  consistent  with  the  ﬁndings  of  previous
studies in  that  the  acquisition  of  ISAba1/blaOXA-23
is  the  main  mechanism  for  carbapenem  resis-
tance among  A.  baumannii  isolates  in  Saudi  Arabia
[13—15].
The blaOXA-24-like gene  has  been  reported  in
Portugal, Spain,  Poland,  Iran,  the  United  States
and Asia  [11,12,21,23,30].  In  Saudi  Arabia,  the
blaOXA-24-like gene  was  detected  at  a  rate  of  4—45%
in Acinetobacter  isolates  [13,14].  It  is  notewor-
thy that  3  (5.4%)  A.  baumannii  isolates  in  our
study were  positive  for  ISAba1/blaOXA-24-like genes.
Our ﬁndings  indicate  that  there  are  different
mechanisms  for  carbapenem  resistance  among  A.
baumannii  isolates  recovered  from  different  Saudi
regions.  The  spread  of  these  genes  among  isolates
deserves further  attention.
In this  study,  the  mechanism  of  carbapenem
resistance  is  not  clear  in  the  12  carbapenem-
resistant  isolates  encoding  the  blaOXA-51 gene  alone
(2 isolates),  the  blaOXA-51/blaOXA-58 combination
(2 isolates)  and  the  blaOXA-51/blaOXA-23 combina-
tion (8  isolates)  as  the  sole  carbapenemase  gene
determinants  that  are  not  associated  with  theF.M.  Elabd  et  al.
SAba1  element.  Further  investigations  are  required
o delineate  the  resistance  mechanism  in  these
solates  (such  as  the  acquisition  of  metallo--
actamases;  MBLs  or  other  ISAb  elements;  ISAba2,
SAba3  or  ISAba4).
This  study  had  some  limitations.  The  ﬁrst  limita-
ion is  the  small  number  of  A.  baumannii  isolates
nd the  short  duration  of  the  study.  Second,  this
as a single  center  study.  Therefore,  our  ﬁndings
ay not  be  generalized  to  other  settings.  Fur-
her molecular-based  epidemiological  multi-center
tudies of  longer  surveillance  duration  are  neces-
ary to  better  understand  the  prevalence  and  distri-
ution  of  the  carpabenemase  genes  and  prevent  the
pread of  carbapenem-resistant  A.  baumannii  noso-
omial isolates.  These  studies  are  necessary  to  help
etermine  national  priorities  for  local  intervention
fforts.
In conclusion,  our  ﬁndings  further  illustrate  the
hallenge  of  increasing  carbapenem-resistance  in
. baumannii  isolates  in  Saudi  Arabia.  The  high
istribution  of  class  D  carbapenemase-encoding
enes, mainly  ISAba1/OXA-23  and  ISAba1/OXA-
4  carbapenemases,  presents  an  emerging  threat
n our  hospital.  The  diversity  of  resistance
enes is  particularly  worrisome  due  to  the  dif-
cult choice  of  empirical  antibiotic  therapy  in
eriously  ill  patients  and  the  possible  contribu-
ion to  increased  hospital  stay  and  associated
osts. Moreover,  local  molecular  surveillance  is
ssential  to  help  control  carbapenem-resistant
. baumannii  nosocomial  infections  and  to  pre-
ent DNA  exchange  among  endemic  nosocomial
athogens.
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